AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05802589 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no peripheral block
Description: No peripheral block was applied. Standard multimodal analgesia method was applied.
Study NCT05011812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451 Dose 1
Description: Dose level 1 of PBI-0451
Study NCT05011812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451 Dose 2
Description: Dose level 2 of PBI-0451
Study NCT05011812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451 Dose 3
Description: Dose level 3 of PBI-0451
Study NCT05385432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Simulect® IV 40mg D0 and D4
Study NCT05011812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451 Dose 4
Description: Dose level 4 of PBI-0451
Study NCT05011812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir will be co-administered with the study drug in Treatments J and K
Study NCT05903352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Continue the antimicrobial treatment
Description: Continue the antimicrobial treatment for a duration predetermined by the investigator (usual practice, at least 5 days of treatment in total).
Study NCT05426785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1:1 ratio for Treatment Group and Control Group
Description: Randomization also will be performed at latest 10 days after ICD implantation, and the specified device programming settings for the allocated group will be set after successful implantation of the investigational devices.
Study NCT05011812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be co-administered with the study drug in Treatment L
Study NCT05011812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match
Study NCT05729321 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: neutrox
Description: Each ECC, after discontinuing the Parental Nutrition (NP) infusion, will be flushed with 0.3 ml saline. Subsequently, Saline will be infused at a rate of 2 ml/h for 10 minutes. The ECC will then be closed for 1 hour. At the end of the hour the ECC will be once again flushed with 0.3 ml Saline and infused with SF at the rate of 2 cc/h for 10 minutes. The difference in pressure of the two infusions, before and after catheter closure, will be evaluated.
Study NCT05106907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ThisCART19 cells
Description: 0.2-60 x 10\^6 CAR T cells per kg body weight
Study NCT04763967 — intervention group
Intervention type: DEVICE
Intervention: PedSCath Pediatric Urinary Catheter
Description: PedSCath Pediatric Sampling Catheter is a pediatric sampling catheter. The product is supplied as a catheter and syringe. PedSCath Pediatric Sampling Catheter is manufactured by Medical Murray Inc. for Big Blue Biotech. The device consists of a blend of LDPE/Elvax/Crodamide.
Study NCT04763967 — intervention group
Intervention type: DEVICE
Intervention: Standard of Care
Description: Current Standard of Care for pediatric patients
Study NCT05129696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment (T)
Description: Children area offered to participate in bimonthly group sessions. Each session will have materials and activities appropriate for children spanning a 6-month range (6-12 m, 12-18 m, 12-24 m, 24-30 m) and can accommodate a maximum of 10 children per age group. If more households are interested than can be accommodated by the program, interested families will be randomly selected for participation. A total of 40 children per site will be able to participate in the ECD activities at any one time. With bi-monthly meetings, each child will be exposed to 12 sessions for each age group, and is eligible to transition to the next.
Study NCT05129696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment + (T+)
Description: Caregivers/children participating to the group ECD sessions will be invited to play within a play space equipped with books, and homemade/purchased age-appropriate toys. This will be phased in after 6 months of implementation.
Study NCT05011812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451
Description: Dose level of PBI-0451 with a projected exposure
Study NCT05011812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-0451 Dose 5
Description: Dose level 5 of PBI-0451
Study NCT04804683 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic dissection of Fibromuscular Dysplasia
Description: Blood sampling for genetic analysis aiming at unraveling the genetic basis of Fibromuscular Dysplasia
Study NCT04804683 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Search for diagnostic and prognostic biomarkers of Fibromuscular Dysplasia
Description: Blood/urine and in rare cases tissue sampling aiming at identifying biomarkers of Fibromuscular Dysplasia
Study NCT06106126 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GST-HG171 Tablets
Description: 150mg GST-HG171 100mg Tablets and ritonavir
Study NCT00687180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with mycophenolat mofetil
Study NCT00687180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with azathioprin
Study NCT06007521 — intervention group
Intervention type: OTHER
Intervention: interview with neurologist
Description: interview with neurologist
Study NCT04932109 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention in this group
Study NCT04670211 — intervention group
Intervention type: DEVICE
Intervention: maxillary distractor
Description: the type of maxillary distractor: tooth-borne, bone-borne or hybrid distractor
Study NCT06102551 — intervention group
Intervention type: BEHAVIORAL
Intervention: Recurrence after surgery
Description: Recurrence after repair was the main outcome
Study NCT05203315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duobrii 0.01 % / 0.045 % Topical Lotion
Description: Duobrii® lotion (halobetasol propionate \[HP\] and tazarotene \[Taz\] 0.01%/0.045%) is currently on the market for the treatment of moderate to severe stable plaque psoriasis, and is classified as a high potency (Class II) corticosteroid.
Study NCT05203315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CeraVe, Topical Cream
Description: CeraVe cream will be used twice daily (in the morning and again in the evening) by the study participant in conjunction with Duobrii and Hydrocortisone cream.
Study NCT05181072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced in-person peer-motivation smoking cessation
Description: Tobacco cessation classes will be offered in-person for a total of five sessions delivered weekly for five weeks and will utilize the CEASE Today Tobacco This is a seven-week tobacco cessation program and will be offered in-person weekly for seven weeks and will utilize the CEASE Today Tobacco Cessation Manual.
Study NCT05181072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual peer-motivation smoking cessation
Description: This is a seven-week tobacco cessation program and will be offered virtually (except first two sessions: orientation and technology set-up) weekly for seven weeks and will utilize a newly developed website with smoking cessation modules that mirrors lessons of the CEASE Today Tobacco Cessation Manual
Study NCT04796974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cention
Description: Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Basic Filling Material). Procedures will be done using local anesthesia. The cavity is excavated and filled according to the guidelines for ordinary restorative techniques
Study NCT04984239 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Therapy for aphasia
Description: The intervention will consist of Acceptance and Commitment Therapy modified to meet the needs of stroke survivors with aphasia, combined with communication strategy training.
Study NCT06027203 — intervention group
Intervention type: PROCEDURE
Intervention: prostate biopsy
Description: Prostate biopsy by either transrectal or transperineal technique
Study NCT05822882 — intervention group
Intervention type: PROCEDURE
Intervention: Epidural anesthesia
Description: Postoperative pain management by epidural anesthesia via epidural catheter and pain pump
Study NCT06081543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff for the first 6 weeks. After that will be a free-living diet period where food will not be supplied but participants will receive educational materials and frequent coaching from a dietitian to help maintain the specified diet. Participants will be asked to exclusively follow the diet in efforts to control any dietary effects.
Study NCT06081543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-fat Mixed diet
Description: Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff for the first 6 weeks. After that will be a free-living diet period where food will not be supplied but participants will receive educational materials and frequent coaching from a dietitian to help maintain the specified diet. Participants will be asked to exclusively follow the diet in efforts to control any dietary effects.
Study NCT06142539 — intervention group
Intervention type: RADIATION
Intervention: CT Radiation Doses
Description: Obtaining Low CT Radiation Doses by Adjusting Dose Levels
Study NCT05229185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DeXtreme training (error-enhancement)
Description: 15-20 min DeXtreme - 15 min conventional therapy - 15-20 min DeXtreme
Study NCT06202495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser and Fluoride
Description: topic application of amino-fluoride gel (Elmex Dental Gel, Colgate-Palmolive company, New York, 300 Park Ave, United States) in association 980nm diode laser (doctor smile wiser by Lambda s.p.a. Via dell'Impresa, 1, 36040 Brendola VI, Italy) 1.5 W, pulsed mode 2 mm from tooth surface
Study NCT06202495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride
Description: topic application of amino-fluoride gel (Elmex Dental Gel, Colgate-Palmolive company, New York, 300 Park Ave, United States)
Study NCT06136364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: CAR-T immunotherapy targeting CD7+
Study NCT06109363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT-I)
Description: CBT-I intervention will be provided to participants once their districts are exposed.
Study NCT04874935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: administration of lansoprazole 60 mg twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
Study NCT04874935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administration of Placebo capsule twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
Study NCT05092087 — intervention group
Intervention type: BEHAVIORAL
Intervention: nutrition counseling
Description: nutrition counseling
Study NCT04275037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Handgrip Training
Description: The 8-week exercise program will include three sessions of isometric handgrip training per week
Study NCT04275037 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training
Description: The 8-week exercise program will include three sessions of aerobic exercise per week
Study NCT04708730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delipid Extracorporeal Lipoprotein filter from Plasma
Description: As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke
Study NCT06277310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 Wishes Project
Description: palliative care initiative in which clinicians elicits and implements small acts of kindness for dying patients and their families
Study NCT04877730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully Closed Loop (FCL)
Description: Closed loop without a meal anticipation module without announced carbohydrate
Study NCT04877730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully Closed Loop with meal anticipation module (FCL+)
Description: Closed loop with a meal anticipation module and without announced carbohydrate
Study NCT04877730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Closed Loop (HCL)
Description: Closed loop without a meal anticipation module with announced carbohydrate
Study NCT05929209 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of disease biomarkers
Description: Assessment of serum, histological and radiological biomarkers
Study NCT06349642 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo optional research blood sample.
Study NCT06349642 — intervention group
Intervention type: PROCEDURE
Intervention: Tissue Collection
Description: Tissue specimen collection will be completed with your scheduled standard of care biopsy if possible. If standard of care biopsy is already completed or the research biopsy wasn\&#39;t collected at the time as your standard of care biopsy, then the research biopsy will be scheduled for a different day for research purposes only.
Study NCT04802720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Cancer Caregivers (CBT-C)
Description: The sessions are outlined as follow:~1. psychoeducation, goal-setting, and describing the rationale for CBT (Session 1);~2. coping effectiveness training (Session 2);~3. identifying unhelpful cognitions and dysfunctional beliefs (Session 3);~4. challenging and restructuring unhelpful cognitions (Session 4);~5. behavioral activation within the limitations of the caregiving context (Session 5);~6. problem-solving (Session 6);~7. communication strategies and assertiveness training (Session 7);~8. consolidating gains, maintenance, and relapse prevention (Session 8).
Study NCT04802720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Therapy for Cancer Caregivers (ERT-C)
Description: The sessions are outlined as follow:~1. psychoeducation and motivation/dysregulation cue detection within caregiving contexts (Session 1);~2. attention regulation skills training (Sessions 1-2);~3. training in metacognitive skills (Sessions 3-4);~4. exposure to proactive living in the face of risk and loss while applying skills (Sessions 5-7);~5. consolidating gains, taking larger proactive steps, and relapse prevention (Session 8).
Study NCT00756691 — intervention group
Intervention type: OTHER
Intervention: 18F-FAZA
Description: Radioactive dose of 110-600 MBq per injection. A single pre-treatment injection of 18F-FAZA will be permitted per patient
Study NCT06499493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial induction in gastrocnemius muscle
Description: A 3-pass shallow leg gliding technique was applied first, followed by 5 minutes of the deep myofascial calf induction technique described by Pilat.
Study NCT05167305 — intervention group
Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study
Study NCT06134219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MF course
Description: A course consisting of six 2-hour-meetings every two-weeks with 10-15 participants (12 weeks in total). The meetings have different themes related to MF, such as understanding, practices for a deeper understanding of emotions, balance in everyday life with rest and activity, meditation practice to give time for brain rest, and mindfulness).
Study NCT06134219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual health care
Description: The usual health care consists of one or few follow-up visits with blood tests at Sahlgrenska university hospital in Gothenburg or follow-up at the primary care after the end of treatment for Graves' treatment.
Study NCT06134219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual health care
Description: The usual health care consists of one or few follow-up visits with blood tests at Sahlgrenska university hospital in Gothenburg or follow-up at the primary care after the end of treatment for Graves' treatment.
Study NCT05077930 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: The intervention group will receive 200 or 400 mL of high-titer COVID-19 convalescent plasma, ABO compatible with the patient, within 24 hours of randomization.
Study NCT05077930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: The active comparator group will receive oxygen supplementation, corticoids, antiretrovirals, and/or monoclonal antibodies according to the institutional protocol.
Study NCT04796597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subcutaneous implantation of Epios sub-scalp leads
Description: The sub-scalp Epios Leads will be implanted by a trained neurosurgeon and will provide epicranial EEG recording of specific cortical areas identified by the neurologist.
Study NCT05899361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Guided Laparoscopy
Description: Standard Care
Study NCT05899361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Standard Care
Study NCT06232876 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Blinded continuous vital sign monitoring
Description: Continuous blinded vital sign monitoring.
Study NCT06232876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unblinded continuous vital sign monitoring
Description: Continuous unblinded vital sign monitoring.
Study NCT05414890 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CBA-TSA
Description: Compare the specificity, sensitivity, and clinical correlation between CBA and CBA-TSA, in detecting AQP4, MOG, and NMDAR IgG
Study NCT05466058 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: palpation - ultrasonography
Description: Physical therapist will assess patients to detect site of pathology (A1, A2, A3, A4, A5, midpalm or wrist) then patients will be refereed to radiologist who will detect site of pathology by sonography
Study NCT05827861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HeartAge
Description: HeartAge is a phenotypic age-based risk presentation which is a modified tool for CVD risk communication based on the Framingham risk Score. The Heart-Age risk presentation is the age at which an individual of the same sex would be expected to experience the same absolute risk as the individual, had their risk factors been 'normal' based on the clinical guidelines.
Study NCT05827861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE-CVD Mobile App
Description: The HOPE-CVD mobile app is an evidence-based behaviour change platform that runs for 24 weeks. The programme supports behavioural modification through seven self-care behaviours (active living, exercise, weight management, blood pressure-friendly diet, cholesterol-friendly diet, medication adherence and smoke-free lifestyle). To adopt a digital delivery of Motivational Interviewing and Cognitive Behavioural Therapy, the HOPE-CVD platform incorporates interactive decision aids, dramatic vignettes, expert content, peer videos and behaviour tracking.
Study NCT05827861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genetic Risk Score
Description: Participants will undergo genetic testing from which a genetic risk score for CVD will be estimated. they will receive a genetic risk communication which indicates which quartile of genetic risk they are at in comparison to the rest of the population. The report also contains information on what this risk means for their chances of developing cardiovascular disease in the future.
Study NCT04701892 — intervention group
Intervention type: OTHER
Intervention: Indicators of central sensitisation
Description: Indicators of central sensitisation, assessed by the Central Sensitization Inventory
Study NCT05281159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Information
Description: This group will receive an SMS text message highlighting their risk for CRC on top of the content in the Control arm.
Study NCT05281159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Information + Action
Description: This group will receive an SMS text message highlighting their risk for CRC and the importance of taking quick action, on top of the content in the Control arm.
Study NCT06606210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InnovaMatrix® AC
Description: Weekly dressing applications
Study NCT06602635 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG and clinical score
Description: The Hybrid Score (HS), detailed in previous literature involves a sum of points based on clinical and ECG characteristics. Points are assigned as follows: one point each for being over 50 years old, male, and having arterial hypertension. ECG-based points are allocated according to QRS transition: 3 points for a transition in V1, 2 points for V2, 1 point for V3 if the R-wave in V3 is greater than 1 mV; 1 point is subtracted if V3 has an R-wave less than 1 mV, and further deductions or additions apply for transitions up to V6. A score ≤ 1 suggests an RVOT origin, whereas ≥ 2 suggests an LVOT origin.